Transplanting depleted donor stem cells in patients with Fanconi Anemia using a new conditioning treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to develop a novel cell therapy for patients with Fanconi Anemia by using depleted donor stem cells after conditioning with an experimental antibody treatment called JSP-191. The goal is to enhance hematopoietic and immune reconstitution while reducing toxicity compared to traditional chemotherapy methods. Participants will receive the conditioning regimen, followed by the stem cell infusion, and will be monitored for up to two years post-infusion to assess outcomes and side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

All patients must have:

1. Fanconi Anemia diagnosis as demonstrated by abnormal chromosome breakage studies with increased sensitivity to mitomycin-C (MMC) or diepoxybutane (DEB) and at least one mutation in a known Fanconi-associated gene
2. Bone marrow failure (defined by reduction in at least one cell line on two separate occasions at least one month apart (e.g., platelet count of \<100,000 per cubic millimeter, hemoglobin \<9 gm/dl and/or absolute neutrophil count (ANC) of \<1000/mm)
3. Age of ≥2 years
4. Consenting ≥5/10 HLA-matched related or unrelated donor available for apheresis
5. Organ function defined as:

   1. Serum Creatinine \<2.0 mg/dL and corrected creatinine clearance/cystatin cL \>60 mL/min/1.73m\^2 without dialysis
   2. Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO) corrected for hemoglobin and volume, \>50% predicted by pulmonary function tests (PFTs)
   3. For patients unable to cooperate for PFTs, criteria are no evidence of dyspnea at rest, no exercise intolerance, and no requirement for supplemental oxygen with spO2 \>93%
   4. Shortening fraction of ≥29% or ejection fraction of ≥45% by echocardiogram
   5. Serum total bilirubin of \<4 x ULN
   6. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 5 x ULN
   7. Prothrombin time international normalized ratio (PT INR) and partial thromboplastin time (PTT) \<1.5 x ULN
6. Life expectancy of at least 2 years
7. Patients of childbearing potential must be willing to use an effective contraceptive method for the duration of the peri-transplant conditioning through hematopoietic recovery
8. Patients and/or parents or legal guardians must be able to provide written informed consent and authorize use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act

Exclusion Criteria:

1. Patients with available and consenting 10/10 HLA-identical sibling donor for apheresis
2. Patients with any acute or uncontrolled infections at the time of enrollment, including bacterial, fungal or viral
3. Patients who are seropositive for HIV-I/II or HTLV-I/II.
4. Patients receiving any other investigational agents or other biological, chemotherapy, or radiation therapy within 14 days of enrollment
5. Patients with any active malignancies, myelodysplastic syndrome or other concerns for high-risk bone marrow disease
6. Patients who received androgens in last 3 months
7. Pregnant or lactating women
8. Women who are nursing and do not wish to discontinue breastfeeding
9. Lansky/Karnofsky performance score \<50%.
10. Any other medical condition or history that, in the opinion of the Principal Investigator, could pose a significant safety risk to the participant or jeopardize the integrity of the study
11. Patients who, in the opinion of the Principal Investigator, may not be able to comply with the safety monitoring requirements of the study

Where it's running

• Stanford University
  Stanford, California, United States Recruiting

Study contacts

• Principal investigator: Rajni Agarwal, MD — Stanford University

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia

  This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.

  Recruiting at 2 sites Phase 1 Rockefeller University · Minneapolis, Minnesota and 1 other locations · NCT07901959

• Understanding congenital bone marrow failure and related disorders through a national network

  This project tests whether people with rare inherited bone marrow failure syndromes or related conditions really have the underlying genetic causes, by collecting data and samples across multiple centers.

  Recruiting at 4 sites Istituto Giannina Gaslini · Avellino and 3 other locations · NCT07877727

• MRI-based noninvasive detection and monitoring of oral lesions in people with Fanconi anemia

  This study tests whether MRI and dedicated dental MRI can help detect and track potential oral cancers or precancers in people with Fanconi anemia without surgery or biopsy.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07649031

• Using Afatinib to treat patients with Fanconi Anemia and advanced head and neck cancer

  This study is testing if Afatinib can help people with advanced head and neck cancer who also have Fanconi Anemia feel better and improve their condition.

  Recruiting at 2 sites Phase 1/2 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Hanover and 1 other locations · NCT06648096

• Investigating how acetaldehyde contributes to oral cancer development

  This study is trying to see how drinking alcohol affects the development of oral cancer in healthy people and those with Fanconi anemia by looking at samples like saliva and urine.

  Recruiting Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05973656

• Understanding Squamous Cell Carcinoma in People with Fanconi Anemia

  This study looks at how squamous cell carcinoma develops in people with Fanconi anemia to help catch it early and improve treatment options.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05687149

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.